Novartis Pressures Generics Makers Over Exforge ANDA
In two complaints filed in Delaware federal court, Novartis claims that Lupin, Torrent and their affiliates infringed Novartis' patent for Exforge by filing abbreviated new drug applications with the U.S. Food and Drug Administration before the expiration of the drug's patent, which is listed under the generic name valsartan.
"On information and...
Already a subscriber? Click here to login